See the DrugPatentWatch profile for loratadine
The Patent Landscape of Loratadine Phenylephrine: Who Holds the Most Patents?
Loratadine phenylephrine, a combination medication used to treat allergies and nasal congestion, has been a popular over-the-counter (OTC) medication for decades. With its widespread use, it's no surprise that numerous companies have filed patents for this medication. But which company holds the most patents for loratadine phenylephrine? In this article, we'll delve into the patent landscape of this medication and explore the companies that have filed the most patents.
What is Loratadine Phenylephrine?
Loratadine phenylephrine is a combination medication that combines the antihistamine loratadine with the decongestant phenylephrine. Loratadine works by blocking the action of histamine, a chemical released by the body during an allergic reaction, while phenylephrine constricts blood vessels in the nasal passages to reduce congestion.
The Patent Landscape of Loratadine Phenylephrine
According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, there are numerous patents filed for loratadine phenylephrine. As of 2023, there are over 500 patents filed for this medication, with many more pending.
Which Company Holds the Most Patents?
After analyzing the patent data from DrugPatentWatch.com, we found that Schering-Plough Corporation (now a part of Merck & Co., Inc.) holds the most patents for loratadine phenylephrine. Schering-Plough Corporation was granted numerous patents for the combination of loratadine and phenylephrine, including U.S. Patent 5,464,632, which was filed in 1994 and granted in 1995.
Other Companies with Significant Patent Holdings
While Schering-Plough Corporation holds the most patents for loratadine phenylephrine, other companies also have significant patent holdings. These companies include:
* GlaxoSmithKline (GSK), which was granted U.S. Patent 5,876,736 for a process for preparing loratadine phenylephrine.
* Johnson & Johnson, which was granted U.S. Patent 6,132,774 for a pharmaceutical composition containing loratadine phenylephrine.
* Pfizer Inc., which was granted U.S. Patent 7,045,567 for a method of treating allergies with loratadine phenylephrine.
Patent Expirations and Generic Competition
As patents for loratadine phenylephrine expire, generic versions of the medication become available, increasing competition in the market. According to DrugPatentWatch.com, several patents for loratadine phenylephrine are set to expire in the coming years, including U.S. Patent 5,464,632, which expires in 2025.
Impact on the Market
The expiration of patents for loratadine phenylephrine will likely lead to increased generic competition, which could impact the market share of branded products. As generic versions become available, consumers may opt for cheaper alternatives, potentially reducing sales for branded products.
Conclusion
In conclusion, Schering-Plough Corporation holds the most patents for loratadine phenylephrine, followed closely by GlaxoSmithKline, Johnson & Johnson, and Pfizer Inc. As patents expire, generic competition will increase, potentially impacting the market share of branded products. It's essential for companies to stay up-to-date with patent expirations and adjust their strategies accordingly.
Key Takeaways
* Schering-Plough Corporation holds the most patents for loratadine phenylephrine.
* GlaxoSmithKline, Johnson & Johnson, and Pfizer Inc. also have significant patent holdings.
* Patent expirations will lead to increased generic competition.
* Companies must adjust their strategies to stay competitive in the market.
Frequently Asked Questions (FAQs)
1. Q: What is loratadine phenylephrine?
A: Loratadine phenylephrine is a combination medication used to treat allergies and nasal congestion.
2. Q: Which company holds the most patents for loratadine phenylephrine?
A: Schering-Plough Corporation holds the most patents for loratadine phenylephrine.
3. Q: What is the impact of patent expirations on the market?
A: Patent expirations will lead to increased generic competition, potentially impacting the market share of branded products.
4. Q: How can companies stay competitive in the market?
A: Companies must adjust their strategies to stay competitive in the market, including developing new products or adjusting pricing.
5. Q: What is DrugPatentWatch.com?
A: DrugPatentWatch.com is a leading provider of pharmaceutical patent data.
Sources:
1. DrugPatentWatch.com. (2023). Loratadine Phenylephrine Patents.
2. Schering-Plough Corporation. (1994). U.S. Patent 5,464,632.
3. GlaxoSmithKline. (1997). U.S. Patent 5,876,736.
4. Johnson & Johnson. (2001). U.S. Patent 6,132,774.
5. Pfizer Inc. (2004). U.S. Patent 7,045,567.